Comparative Evaluation of the Efficacy and Safety of High-Power Short-Duration Radiofrequency Ablation and Standard Low-Power Ablation in Catheter Treatment of Atrial Fibrillation
Recruiting now · Not applicable
Conditions studied: Atrial Fibrillation (AF), Stroke, Acute Cerebrovascular Accident, Atrial Fibrillation Recurrent, Death
In brief
Atrial fibrillation (AF) is the most common cardiac arrhythmia and represents one of the leading causes of cardiovascular morbidity and mortality. According to current data, AF is associated with approximately 20% of all ischemic strokes, while the risk of stroke in patients with this arrhythmia is increased fivefold. Ischemic stroke in patients with AF is characterized by a more severe clinical course, more frequently results in death, is associated with significant disability, and carries a higher risk of recurrence compared with strokes of other etiologies. Consequently, the risk of death in patients with AF-associated stroke is doubled, while the economic costs of treatment increase by an average of 1.5 times. The aim of the present study is to perform a comparative evaluation of the efficacy of two interventional treatment strategies for atrial fibrillation: very high-power short-duration radiofrequency ablation (90 W) and conventional low-power radiofrequency ablation (35-45 W) for pulmonary vein isolation using the "CLOSE protocol" approach with a non-fluoroscopic navigation system. The efficacy of the interventions will be assessed both in the early postoperative period and during long-term follow-up over 12 months.
Key facts
- Study ID
- NCT07728539
- Run by
- Bakulev Scientific Center of Cardiovascular Surgery
- People needed
- 196
- Starts
- 2026-06-15
- Expected to finish
- 2029-06-01
- Last updated by the study team
- 2026-07-27
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age over 18 years old;
- Atrial fibrillation resistant to antiarrhythmic therapy;
- Paroxysmal form of atrial fibrillation;
- Persistent form of atrial fibrillation;
- The patient's consent to participate in the study.
You may not qualify if…
- Exclusion Criteria:
- Age under 18 and over 80 years old;
- The presence of another cardiac pathology requiring surgical treatment;
- Congenital heart defects;
- Previous "open" cardiac surgery;
- Bone marrow diseases;
- Pathology of the blood coagulation system;
- The left ventricular ejection fraction is less than 40%;
- Moderate to severe renal insufficiency (creatinine clearance <50 ml/min);
- Drug-resistant hypertension (despite hypotensive therapy);
- Organically altered mitral valve;
- There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons;
- The patient's participation in another clinical trial.
Where it is running
- Bakulev National Medical Research Center for Cardiovascular Surgery — Moscow, Russia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.